Enzo Galligioni
University of Verona
CancerInternal medicineUrologySurgeryPathologyOncologyRetrospective cohort studyAbiraterone acetateEnzalutamideChemotherapyProstate cancerGemcitabineDocetaxelToxicityIn patientCastration resistantRadiation therapyBreast cancerMedicineGastroenterology
257Publications
25H-index
2,872Citations
Publications 254
Newest
#1Orazio CaffoH-Index: 36
#2Ugo De GiorgiH-Index: 55
Last. Enzo GalligioniH-Index: 25
view all 20 authors...
230Background: High NLR has been reported to be a poor prognostic indicator in both first and second mCRPC lines, while no information is available concerning this issue in pts treated in third line therapy. The present study is aimed to assess the possible relationship between third line clinical outcomes and NLR in a series of mCRPC pts treated with a NA [abiraterone acetate (AA), cabazitaxel (CABA), or enzalutamide (ENZ)] after the failure of docetaxel (DOC) and another NA. Methods: We collec...
Source
#1Antonello VecciaH-Index: 14
#2Francesca MainesH-Index: 17
Last. Orazio CaffoH-Index: 36
view all 5 authors...
Prostate cancer is typically diagnosed in men ≥65 years of age, many of whom have one or more comorbidities, often including cardiovascular comorbidities, thus highlighting a need to understand the risks of cardiovascular toxicities associated with prostate cancer treatments. In this Review, the authors describe the evidence linking widely used treatments of prostate cancer, including androgen deprivation therapies, chemotherapies and targeted therapies with cardiovascular adverse events.
9 CitationsSource
#1Orazio CaffoH-Index: 36
#2C. Thompson (University of Manchester)H-Index: 2
Last. Ananya Choudhury (University of Manchester)H-Index: 28
view all 10 authors...
Abstract Purpose Although radical cystectomy is still considered the standard of care for most localized muscle-invasive bladder cancer (MIBC) patients, bladder-sparing strategies with chemoradiotherapy have demonstrated comparable local control and survival rates when adjusting for tumor stage. We present a pooled analysis of individual patient data out of published trials with gemcitabine-based chemoradiotherapy for MIBC. Methods and materials Individual patient data were collected from Instit...
24 CitationsSource
#2S. BrugnaraH-Index: 5
Last. Enzo GalligioniH-Index: 25
view all 10 authors...
Source
#1Antonello VecciaH-Index: 14
#2Orazio CaffoH-Index: 36
Last. Enzo GalligioniH-Index: 25
view all 9 authors...
Source
#1Orazio CaffoH-Index: 36
#2Andrea Lunardi (University of Trento)H-Index: 2
Last. Enzo GalligioniH-Index: 25
view all 6 authors...
The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidenc...
4 CitationsSource
#1Orazio CaffoH-Index: 36
#2Francesca MainesH-Index: 17
Last. Enzo GalligioniH-Index: 25
view all 5 authors...
Over the last ten years, two new-generation hormonal drugs and two chemotherapeutic agents have been approved for the treatment of metastatic castration-resistant prostate cancer. Unfortunately, some patients have primary resistance to them and the others eventually develop secondary resistance. It has recently been suggested that the presence of androgen receptor splice variants plays a leading role in the primary and secondary resistance to the new hormonal drugs, whereas their presence seem t...
4 CitationsSource
#2Orazio CaffoH-Index: 36
Last. Enzo GalligioniH-Index: 25
view all 20 authors...
e20594Background: BM development, which is frequently observed in pts with NSCLC, is usually associated with a poor outcome. Systemic treatments and whole brain radiotherapy (WBRT) are widely used ...
Source
#1Antonello VecciaH-Index: 14
#2Orazio CaffoH-Index: 36
Last. Enzo GalligioniH-Index: 25
view all 8 authors...
Source
#1Dante AmelioH-Index: 13
#2L. WidesottH-Index: 13
Last. Maurizio AmichettiH-Index: 30
view all 15 authors...
Source